Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease

Jing-Fei Chen,Kun Liu,Bo Hu,Rong-Rong Li,Wendy Xin,Hao Chen,Fei Wang,Lin Chen,Rui-Xue Li,Shu-Yu Ren,Lan Xiao,Jonah R Chan,Feng Mei,Jonah R. Chan
DOI: https://doi.org/10.1016/j.neuron.2021.05.012
IF: 16.2
2021-07-01
Neuron
Abstract:Severe cognitive decline is a hallmark of Alzheimer's disease (AD). In addition to gray matter loss, significant white matter pathology has been identified in AD patients. Here, we characterized the dynamics of myelin generation and loss in the APP/PS1 mouse model of AD. Unexpectedly, we observed a dramatic increase in the rate of new myelin formation in APP/PS1 mice, reminiscent of the robust oligodendroglial response to demyelination. Despite this increase, overall levels of myelination are decreased in the cortex and hippocampus of APP/PS1 mice and postmortem AD tissue. Genetically or pharmacologically enhancing myelin renewal, by oligodendroglial deletion of the muscarinic M1 receptor or systemic administration of the pro-myelinating drug clemastine, improved the performance of APP/PS1 mice in memory-related tasks and increased hippocampal sharp wave ripples. Taken together, these results demonstrate the potential of enhancing myelination as a therapeutic strategy to alleviate AD-related cognitive impairment.
neurosciences
What problem does this paper attempt to address?